Lead Product(s) : Undisclosed
Therapeutic Area : Nutrition and Weight Loss
Study Phase : Discovery Platform
Sponsor : Eli Lilly
Deal Size : $650.0 million
Deal Type : Collaboration
Eli Lilly inks $650M Juvena pact to find muscle-boosting drugs
Details : The collaboration with Lilly will help to identify muscle targeting drug candidates from Juvena’s library of human stem-cell secreted proteins for improved body composition & muscle health.
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Undisclosed
June 11, 2025
Lead Product(s) : Undisclosed
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Discovery Platform
Sponsor : Eli Lilly
Deal Size : $650.0 million
Deal Type : Collaboration
Lead Product(s) : Undisclosed
Therapeutic Area : Nutrition and Weight Loss
Study Phase : Discovery Platform
Sponsor : Novo Nordisk
Deal Size : $812.0 million
Deal Type : Collaboration
Novo Nordisk Inks $812M Deep Apple Deal to Pursue Obesity Target
Details : The collaboration aims to discover, develop, and commercialize oral small molecule therapeutics directed at a novel non-incretin GPCR target for cardiometabolic diseases, including obesity.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
June 11, 2025
Lead Product(s) : Undisclosed
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Discovery Platform
Sponsor : Novo Nordisk
Deal Size : $812.0 million
Deal Type : Collaboration
Lead Product(s) : Undisclosed
Therapeutic Area : Nutrition and Weight Loss
Study Phase : Discovery Platform
Sponsor : Flagship Pioneering
Deal Size : Undisclosed
Deal Type : Agreement
Flagship Pioneering and ProFound Collaborate on First-in-Class Therapeutics for Obesity
Details : ProFound will deploy its proprietary ProFoundry Platform in collaboration with Pioneering Medicines' expertise to discover novel proteins and evaluate their therapeutic relevance for obesity.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
December 06, 2024
Lead Product(s) : Undisclosed
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Discovery Platform
Sponsor : Flagship Pioneering
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : Undisclosed
Therapeutic Area : Nutrition and Weight Loss
Study Phase : Discovery Platform
Sponsor : Flagship Pioneering
Deal Size : Undisclosed
Deal Type : Collaboration
Flagship Pioneering Signs Two Agreements Under Pfizer Strategic Partnership
Details : Under the collaboration, Ampersand's AND™ Platform will be used to identify programmed biologics for the treatment of obesity-related targets.
Product Name : Undisclosed
Product Type : Other Large Molecule
Upfront Cash : Undisclosed
November 20, 2024
Lead Product(s) : Undisclosed
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Discovery Platform
Sponsor : Flagship Pioneering
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : Undisclosed
Therapeutic Area : Nutrition and Weight Loss
Study Phase : Discovery Platform
Sponsor : Novo Nordisk
Deal Size : $530.0 million
Deal Type : Collaboration
Korro Bio Announces Collaboration with Novo Nordisk to Develop Two Therapeutic Candidates
Details : The collaboration brings together Novo's deep cardiometabolic disease understanding and drug development experience with Korro’s platform to develop RNA editing product candidates.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
September 16, 2024
Lead Product(s) : Undisclosed
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Discovery Platform
Sponsor : Novo Nordisk
Deal Size : $530.0 million
Deal Type : Collaboration
Lead Product(s) : Undisclosed
Therapeutic Area : Nutrition and Weight Loss
Study Phase : Discovery Platform
Sponsor : Novo Nordisk
Deal Size : $600.0 million
Deal Type : Collaboration
Flagship Pioneering and Metaphore Biotechnologies Collaborate with Novo on Obesity
Details : Under the collaboration, Novo will leverage Metaphore's MIMICTM platform in the discovery and development of two multitarget therapeutics leveraging GLP-1R and related biology for obesity.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
September 05, 2024
Lead Product(s) : Undisclosed
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Discovery Platform
Sponsor : Novo Nordisk
Deal Size : $600.0 million
Deal Type : Collaboration
Lead Product(s) : Undisclosed
Therapeutic Area : Nutrition and Weight Loss
Study Phase : Discovery Platform
Sponsor : Novo Nordisk
Deal Size : $532.0 million
Deal Type : Collaboration
Novo Nordisk Partners with Omega and Cellarity On Cardiometabolic Disease Treatments
Details : The collaboration leverages Omega's platform to develop an epigenomic controller aimed at enhancing metabolism for obesity treatment.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
April 01, 2024
Lead Product(s) : Undisclosed
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Discovery Platform
Sponsor : Novo Nordisk
Deal Size : $532.0 million
Deal Type : Collaboration